Koramin
Heart cytamin — Khavinson-school organ peptide fraction, oral tablet
Koramin (Heart cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal heart tissue and pressed into a 155mg tablet — the older CYTAMIN line rather than the synthetic cytogens or the cytomax capsules already covered here. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. Heart tissue is one of the four organs where that claim was actually tested: synthetic peptides including cardiogen were applied to heart explants from young and old rats and reported to raise the growth zone. That experiment used defined synthetic peptides on tissue in a dish, not a swallowed extract.
Koramin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The single PubMed record bearing the name is a 1947 Austrian paper about a different drug. |
The one PubMed record that carries this product's name is from 1947 and is about nikethamide, a respiratory stimulant sold as Coramine, in a paper on bronchial asthma. It is a name collision, not a citation, and anyone who searches will find it. What does exist for the heart in this school is an explant experiment using synthetic peptides on rat tissue in a dish. The gap between that and a tablet is two barriers wide and neither has been measured for this product.
How Koramin works
A polypeptide fraction extracted from animal heart tissue and pressed into a 155mg tablet — the older CYTAMIN line rather than the synthetic cytogens or the cytomax capsules already covered here. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. Heart tissue is one of the four organs where that claim was actually tested: synthetic peptides including cardiogen were applied to heart explants from young and old rats and reported to raise the growth zone. That experiment used defined synthetic peptides on tissue in a dish, not a swallowed extract.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Koramin
Buy Koramin at RUPharma →The evidence for Koramin
Graded by what exists behind each claim.
✅ Clinically validated
- None. A PubTator3 search of PubMed for this product's name, run 8 September 2026, returned exactly one record — a 1947 Austrian paper on treating bronchial asthma with Koramin, which in that paper is nikethamide, the respiratory stimulant sold as Coramine. A name collision, not a study of this tablet.
📊 Correlative data
- Heart is one of the few organs where the tissue-specificity claim was tested at all: synthetic peptide bioregulators including cardiogen were applied to organotypic cultures of heart from young and old rats with tissue-matched effects on the growth zone (Zakutskii 2006). Defined synthetic peptides, on tissue in a dish.
- The nearest cardiac human report in this school is epithalamin — the pineal extract, given by injection — in climacteric myocardiopathy (Komarov 1995). Different organ, different product, different route.
🧪 Theoretical / extrapolated
- The class premise is that peptides released from an organ fraction reach the matching organ and alter gene transcription there. For a heart product that requires digestion to be survived, cardiac tissue to be reached, and something to happen there that a general amino acid supply would not. None of the three has been measured.
- The heart is the easiest organ on this shelf for an oral extract to reach, because unlike the brain it sits behind no second barrier — cardiac muscle takes a large share of resting cardiac output. That makes the gut the whole question, and no absorption study exists.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Koramin actually does
Search this product's name and the first thing you find is a different drug. A PubTator3 query for koramin against PubMed, run 8 September 2026, returns exactly one record: Spitzer 1947, a paper on treating bronchial asthma, published in an Austrian journal in 1947. Koramin there is nikethamide, the respiratory analeptic sold as Coramine, and it has no relationship of any kind to a heart-tissue tablet first marketed in the 1990s. Two products, one string of letters, half a century apart. Anyone checking this page's sources will hit that record, so it is named here rather than left to look like a citation somebody missed.
What the tablet is, said without decoration. A 155 mg pressed tablet of a nucleoprotein fraction extracted from animal heart muscle, 40 to a pack, listed by a partner at $42. No composition is published for it anywhere: no peptide profile, no molecular weight distribution, no assay. The nearest thing the school has ever published to a composition paper is Ryzhak 2003, which describes the manufacturing principle and the infectious-agent controls rather than the contents of any one product.
Heart is one of the few organs where the tissue-specificity claim was actually tested, and the test used different molecules. Zakutskiĭ 2006 applied synthetic peptide bioregulators — cardiogen among them — to organotypic cultures of heart, lung, prostate and pancreas taken from young and old rats, and reported tissue-matched stimulation of the explant growth zone. That is four defined amino acids pipetted onto a fragment of heart in a dish. It is not a swallowed extract, and the distance between the two is the whole content of this page.
The class story and what would have to be true for it. The sales premise is that short peptides liberated from an organ fraction reach the matching organ and alter which genes its cells transcribe Khavinson 2021. For a heart product that requires three things in series that nobody has demonstrated: that a peptide survives digestion, that it reaches cardiac tissue, and that it does something there that a general amino acid supply would not. Not one of the three has been measured for this tablet.
Cell, rodent, human — and where it stops
The human rung of this ladder is empty, and the nearest paper to it is about a different organ. The only cardiac clinical work in this whole school is Komarov 1995, a 1995 Russian report of epithalamin in climacteric myocardiopathy. Epithalamin is the pineal extract, given by injection, in menopausal women. It is cited here for what it is — the closest the school comes to a heart outcome — and it is not evidence about a heart extract taken by mouth.
The two human papers that name this product class at all. Khavinson 2001 is a 2001 Russian military-medicine paper on cytamines for professional ability and longevity in servicemen, co-authored by Khavinson himself. It is a class paper: it is about cytamines, not about the heart one. There is no randomization described in its abstract, no placebo arm named, and no cardiac endpoint reported. That is the top of the evidence ladder for this shelf.
The cell rung, with its concentration written out. Ryzhak 2015 applied calf-tissue polypeptide preparations to matching organotypic cultures from young and old rats at 0.01 to 100 ng/ml. Those are nanograms per milliliter, applied directly to tissue in a dish, of a preparation made for injection. The product on sale is a 155 mg tablet, and no experiment has ever connected the two numbers.
Where the chain breaks, in one sentence. Every positive result above was produced by putting material onto tissue or into an animal by needle, and the missing step is the first one the product requires — that anything measurable survives the stomach and crosses the gut wall. For the heart, unlike the brain, there is no second barrier to argue about, which makes the gut the entire question and the absence of any absorption study the entire answer.
Koramin pharmacokinetics — how much of it actually gets in
What degrades it. A nucleoprotein complex is protein plus nucleic acid. Gastric acid denatures it, pepsin cleaves it, pancreatic proteases continue, and brush-border peptidases finish by hydrolyzing what remains to free amino acids and di- and tripeptides. That is not a hypothesis about this product, it is what happens to dietary protein, and no enteric coating, dissolution profile or protease-resistance claim is published for this tablet.
The oral barrier, and why it is the only barrier here. Intact peptides crossing the gut wall do so through saturable carriers, and the fraction that arrives unhydrolyzed is small for anything larger than three residues. A brain product then meets a second barrier; a heart product does not. Cardiac muscle is perfused by a fifth of resting cardiac output, so anything that reaches the blood reaches the heart. That makes this the strongest oral case on the cytamin shelf, and it is still a case nobody has tested.
The arithmetic, run in the product's favor. One 155 mg tablet dissolved intact into 5 liters of blood is about 31 µg/ml. The explant experiments worked at 0.01-100 ng/ml Ryzhak 2015, so even at 0.1% intact absorption the blood concentration would sit at about 31 ng/ml — inside the range that did something to tissue in a dish. The honest reading of that is not that the product works. It is that the objection to it cannot be a simple dilution argument, and has to be the absence of any measurement at all.
Half-life cannot be stated, and the reason is worth naming. No analytical method has been published for this preparation, so there is no analyte to follow in plasma and no injectable comparator to anchor it against — unlike the brain arm of this family, where a radiolabeled injection produced a real tissue-penetration number. The shape that can be stated: amino acids and small peptides released from a protein meal clear over hours, so any pharmacology would be a transient event tied to each dose. The 40-tablet pack describes a course, not a pharmacokinetic profile.
What would have to be true, and how you would know it was not
Four predictions, and the first two can be run at home this month.
1. Resting heart rate and blood pressure, morning, for the length of one pack. Both are free, both are measured by devices most readers already own, and both are the crudest possible test of a product sold for the heart. Zero published records of this tablet report either. Forty mornings of readings before and during a pack would produce more human cardiac data on Koramin than exists anywhere.
2. hs-CRP and a lipid panel, baseline and at the end of a course. Both are standardized worldwide and cost less than the pack. If a heart-tissue extract does anything systemic at 155 mg, inflammation and lipids are the two cheapest places it could show. Prediction: neither moves outside assay noise, and nothing published contradicts that because nothing has been published.
3. Against the product: troponin will not move, and that is the point. A high-sensitivity troponin is the most specific marker of cardiac muscle injury in routine use. It should be flat, because nothing here is proposed to damage myocardium. Naming it is the safety half of falsifiability: if somebody's troponin does rise on this tablet, that is a finding about a person and not a finding about a mechanism, and it belongs in front of a clinician the same day.
4. The comparison the vendor has the least reason to fund. The same catalog sells a heart preparation as a capsule and heart peptides as sublinguals. If the tissue-of-origin premise is real, three presentations of cardiac material should differ from one another on some shared endpoint. Zero such comparisons exist for any organ in this line, and that absence is the most informative fact about the whole product family.
What nobody has tested yet
Nobody has published what is in the tablet. One pack, one dissolution, one liquid chromatography-tandem mass spectrometry run, and a buyer would know the peptide profile and molecular weight distribution of what they are swallowing. Ryzhak 2003 shows the school is capable of that kind of analysis and applies it to the manufacturing process rather than to a finished product. Until somebody publishes it, heart peptide extract names a process, not a substance.
Nobody has drawn blood after a dose. The target range from the explant work is 0.01-100 ng/ml Ryzhak 2015. One volunteer, one tablet, and a series of draws over six hours analyzed for peptide content would say whether the product lands in that range or misses it by orders of magnitude. That is an afternoon of work and it would settle the central question on this page.
Nobody has tested cardiac tissue against cardiac tissue. Zakutskiĭ 2006 used synthetic cardiogen on heart explants. The obvious control — the same assay, same explants, this extract instead of the synthetic peptide — has never been reported, and it is the one experiment that would show whether an extract and a defined peptide behave alike at all.
Extrapolation, labeled as such. If the active principle is a short peptide rather than the intact fraction, three things follow that nobody has tested: the effect should survive deliberate proteolytic digestion of the tablet before dosing, it should be reproducible with the defined synthetic peptides the same school already sells, and it should stop depending on the tissue of origin once the sequence is fixed. The third is the dangerous one, because seventeen organ names are what this line is selling.
Koramin — its own safety story, not its class's
Three things specific to an oral extract of animal heart muscle.
An empty adverse-event column is a measurement of the literature. No adverse event has been published for this product because no study of it has been published; the search on 8 September 2026 returned only a 1947 paper about a different drug. There has never been a setting in which an adverse event could have been recorded and reported. That is the opposite of the position a licensed medicine is in, where a long safety section means somebody counted.
Bovine sourcing is unpublished, and for cardiac tissue that matters less than for brain but is still unanswered. No vendor publishes the source species, the country of origin, the age of the animals or the processing controls for this product. Ryzhak 2003 states that the industrial process for this class uses organs from young animals and is tested by World Health Organization methods, which is the school's own assurance about the class rather than a certificate of analysis for a pack. A buyer cannot check either.
The interaction section is empty for a reason nobody should find reassuring. The readers most likely to buy a heart product are the readers most likely to be taking an anticoagulant, a beta blocker or a statin. There is no interaction data for this tablet with any of them, not because they have been studied and found safe, but because the study has never been done. Anything that has never been tested alongside a prescribed cardiac medicine is a question for the prescriber and not for a page.
Sources read for this page
- Spitzer. Treatment of bronchial Asthma with Koramin. Klinische Medizin (Osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin) 1947 · PMID 20244882
- Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology 2006 · PMID 17152728
- Komarov FI. Use of epithalamin in climacteric myocardiopathy. Klinicheskaia Meditsina (Moskva) 1995 [Russian] · PMID 7474816
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
Koramin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Koramin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Koramin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Koramin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Koramin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Koramin — frequently asked questions
What is Koramin?
Koramin (Heart cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal heart tissue and pressed into a 155mg tablet — the older CYTAMIN line rather than the synthetic cytogens or the cytomax capsules already covered here. The class claim is tissue-specific regulation of gene expression in the organ the extract came from. Heart tissue is one of the four organs where that claim was actually tested: synthetic peptides including cardiogen were applied to heart explants from young and old rats and reported to raise the growth zone. That experiment used defined synthetic peptides on tissue in a dish, not a swallowed extract.
Where can I find Koramin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Koramin protocol are available to members inside Skool. This public page covers what Koramin is, how it works and the evidence.
What is the half-life of Koramin?
Koramin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Koramin?
Current evidence level: No published study of this product. The single PubMed record bearing the name is a 1947 Austrian paper about a different drug.. Koramin is offered for research purposes only and is not an approved medicine.
What Koramin is used for
Koramin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.